Generate Biomedicines Inc (NASDAQ:GENB) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Generate Biomedicines has a consensus “Moderate Buy” rating from eight analysts: six buys, one hold and one sell. The average 12-month price target is $25.40, above the reported share price of $15.99.
• Analyst views are mixed, with Morgan Stanley raising its target to $22 and HC Wainwright increasing its target to $25, while Weiss Ratings initiated coverage with a sell rating and Wall Street Zen downgraded the stock to sell.
• The company reported a quarterly loss of $0.52 per share, missing the $0.48 consensus estimate, on revenue of $6.31 million. Shares have traded between $11.00 and $18.18 over the past year.

Shares of Generate Biomedicines Inc (NASDAQ:GENB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.40.

Several analysts have weighed in on GENB shares. Weiss Ratings began coverage on Generate Biomedicines in a research report on Tuesday, August 11th. They issued a "sell (d)" rating for the company. Wall Street Zen cut shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Morgan Stanley upped their price target on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an "overweight" rating in a report on Thursday, May 14th. Finally, HC Wainwright increased their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, May 8th.

Institutional Trading of Generate Biomedicines

A hedge fund recently bought a new stake in Generate Biomedicines stock. Susquehanna International Group LLP purchased a new stake in shares of Generate Biomedicines Inc (NASDAQ:GENB - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 11,622 shares of the company's stock, valued at approximately $196,000.

Generate Biomedicines Stock Down 5.8%

Shares of NASDAQ:GENB opened at $15.99 on Friday. The company has a market capitalization of $2.05 billion and a PE ratio of -10.06. The company's 50-day moving average is $14.89. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $18.18.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. As a group, research analysts expect that Generate Biomedicines will post -2.29 EPS for the current fiscal year.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source